167 related articles for article (PubMed ID: 9818464)
21. Efficacy and safety of imatinib in patients with chronic myeloid leukemia and complete or near-complete cytogenetic response to interferon-alpha.
Branford S; Hughes T; Milner A; Koelmeyer R; Schwarer A; Arthur C; Filshie R; Moreton S; Lynch K; Taylor K
Cancer; 2007 Aug; 110(4):801-8. PubMed ID: 17607681
[TBL] [Abstract][Full Text] [Related]
22. [Hematologic and cytogenetic response to treatment in patients with chronic myeloid leukemia].
Tóthová E; Fricová M; Stecová N; Kafková A; Mudronová B; Svorcová E; Guman T; Raffac S; Hlebasková M
Cas Lek Cesk; 2000 Jul; 139(14):437-9. PubMed ID: 11048406
[TBL] [Abstract][Full Text] [Related]
23. Interferon alfa versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials: Chronic Myeloid Leukemia Trialists' Collaborative Group.
J Natl Cancer Inst; 1997 Nov; 89(21):1616-20. PubMed ID: 9362160
[TBL] [Abstract][Full Text] [Related]
24. Interferon alpha for chronic myeloid leukemia relapsing after allogeneic bone marrow transplantation.
Steegmann JL; Casado LF; Tomás JF; Sanz-Rodríguez C; Granados E; de la Cámara R; Alegre A; Vázquez L; Ferro MT; Figuera A; Arranz R; Fernández-Rañada JM
Bone Marrow Transplant; 1999 Mar; 23(5):483-8. PubMed ID: 10100563
[TBL] [Abstract][Full Text] [Related]
25. Interferon alpha plus intermittent oral Ara-C ocfosfate (YNK-01) in chronic myeloid leukemia primarily resistant or with minimal cytogenetic response to interferon.
Cervantes F; Sureda A; Hernández-Boluda JC; Martino R; Brunet S; Borrego D; Antich JL; Montserrat E
Haematologica; 2001 Dec; 86(12):1281-6. PubMed ID: 11726320
[TBL] [Abstract][Full Text] [Related]
26. Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment.
Iacobucci I; Rosti G; Amabile M; Poerio A; Soverini S; Cilloni D; Testoni N; Abruzzese E; Montefusco E; Ottaviani E; Iuliano F; Russo D; Gobbi M; Alimena G; Martino B; Terragna C; Pane F; Saglio G; Baccarani M; Martinelli G
J Clin Oncol; 2006 Jan; 24(3):454-9. PubMed ID: 16421422
[TBL] [Abstract][Full Text] [Related]
27. Prognostic significance of additional cytogenetic abnormalities in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha: a Cancer and Leukemia Group B study.
Farag SS; Ruppert AS; Mrózek K; Carroll AJ; Pettenati MJ; Le Beau MM; Peterson BL; Powell BL; Ozer H; Silver RT; Larson RA; Bloomfield CD;
Int J Oncol; 2004 Jul; 25(1):143-51. PubMed ID: 15201999
[TBL] [Abstract][Full Text] [Related]
28. Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis.
Kantarjian HM; O'Brien S; Cortes JE; Shan J; Giles FJ; Rios MB; Faderl SH; Wierda WG; Ferrajoli A; Verstovsek S; Keating MJ; Freireich EJ; Talpaz M
Cancer; 2003 Feb; 97(4):1033-41. PubMed ID: 12569603
[TBL] [Abstract][Full Text] [Related]
29. [Treatment of chronic myeloid leukemia with interferon-alpha].
Szomor A; Molnár L; Nagy A; Dávid M; Alizadeh H; Kecskés M; Vidra T; Kereskai L; Pajor L; Losonczy H
Orv Hetil; 2000 Nov; 141(48):2601-4. PubMed ID: 11141958
[TBL] [Abstract][Full Text] [Related]
30. Restoration of Th1 cytokine synthesis by T cells of patients with chronic myelogenous leukemia in cytogenetic and hematologic remission with interferon-alpha.
Reuben JM; Lee BN; Johnson H; Fritsche H; Kantarjian HM; Talpaz M
Clin Cancer Res; 2000 May; 6(5):1671-7. PubMed ID: 10815885
[TBL] [Abstract][Full Text] [Related]
31. Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients.
Iacobucci I; Saglio G; Rosti G; Testoni N; Pane F; Amabile M; Poerio A; Soverini S; Bassi S; Cilloni D; Bassan R; Breccia M; Lauria F; Izzo B; Merante S; Frassoni F; Paolini S; Montefusco E; Baccarani M; Martinelli G;
Clin Cancer Res; 2006 May; 12(10):3037-42. PubMed ID: 16707599
[TBL] [Abstract][Full Text] [Related]
32. Imatinib mesylate in Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon alpha.
Tóthová E; Kafková A; Fricová M; Benová B; Kirschnerová G; Tóthová A
Neoplasma; 2005; 52(1):63-7. PubMed ID: 15739029
[TBL] [Abstract][Full Text] [Related]
33. A prospective study of alpha-interferon and autologous bone marrow transplantation in chronic myeloid leukemia. The Italian Co-operative Study Group on Chronic Myeloid Leukemia.
Meloni G; Russo D; Baccarani M; Testoni N; Martinelli G; Fanin R; Zuffa E; Rosti G; Alimena G; Saglio G; Mandelli F; Tura S
Haematologica; 1999 Aug; 84(8):707-15. PubMed ID: 10457406
[TBL] [Abstract][Full Text] [Related]
34. Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
Cortes J; Talpaz M; O'Brien S; Giles F; Beth Rios M; Shan J; Faderl S; Garcia-Manero G; Ferrajoli A; Wierda W; Kantarjian H
Cancer; 2003 Sep; 98(6):1105-13. PubMed ID: 12973833
[TBL] [Abstract][Full Text] [Related]
35. [The effectiveness of interferon-alpha therapy in Ph-positive chronic myeloid leukemia].
Bogdanov KV; Frolova OI; Marinets OV; Ogorodnikova IuS; Afanas'ev BV; Zaritskiĭ AIu
Vopr Onkol; 2003; 49(2):189-92. PubMed ID: 12785203
[TBL] [Abstract][Full Text] [Related]
36. [Natural interferon alpha for chronic myelogenous leukemia in the chronic phase: hematologic, cytogenetic and molecular response].
Takeuchi J; Kawamura M; Sawada U; Ohshima T; Horie T; Horikoshi A; Abe T
Rinsho Ketsueki; 1995 Oct; 36(10):1149-56. PubMed ID: 8531323
[TBL] [Abstract][Full Text] [Related]
37. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up.
Lahaye T; Riehm B; Berger U; Paschka P; Müller MC; Kreil S; Merx K; Schwindel U; Schoch C; Hehlmann R; Hochhaus A
Cancer; 2005 Apr; 103(8):1659-69. PubMed ID: 15747376
[TBL] [Abstract][Full Text] [Related]
38. [Analysis of cytogenetic response in Ph+ chronic myeloid leukemia patients treated with interferon alpha].
Hong H; Qiu JY; Lai YY; Shi Y; He Q; Dang H; Lu DP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2003 Jun; 11(3):269-73. PubMed ID: 12844411
[TBL] [Abstract][Full Text] [Related]
39. Effective and safe interferon treatment for Japanese patients with chronic myelogenous leukemia relapse after bone marrow transplantation. The Nagoya Blood and Marrow Transplantation Group.
Sao H; Kato C; Kitaori K; Adachi T; Yano K; Kobayashi M; Kojima H; Tanimoto M; Hirabayashi N; Minami S; Yamada H; Morishita GY; Morishima Y; Kodera Y
Int J Hematol; 2000 Aug; 72(2):237-42. PubMed ID: 11039675
[TBL] [Abstract][Full Text] [Related]
40. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate.
Cortes J; Talpaz M; O'Brien S; Jones D; Luthra R; Shan J; Giles F; Faderl S; Verstovsek S; Garcia-Manero G; Rios MB; Kantarjian H
Clin Cancer Res; 2005 May; 11(9):3425-32. PubMed ID: 15867244
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
